These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 13678730)

  • 21. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.
    Silver DF; Piver MS
    Am J Clin Oncol; 1999 Oct; 22(5):450-2. PubMed ID: 10521056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gemicitabine in the treatment of epithelial ovarian cancer].
    Pautier P; Gutierrez M; Lhomme C
    Bull Cancer; 2002 Aug; 89 Spec No():S115-9. PubMed ID: 12449041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
    Rose PG; Mossbruger K; Fusco N; Smrekar M; Eaton S; Rodriguez M
    Gynecol Oncol; 2003 Jan; 88(1):17-21. PubMed ID: 12504621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience.
    Germano D; Rosati G; Manzione L
    J Chemother; 2007 Oct; 19(5):577-81. PubMed ID: 18073158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
    Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
    Shapiro JD; Millward MJ; Rischin D; Michael M; Walcher V; Francis PA; Toner GC
    Gynecol Oncol; 1996 Oct; 63(1):89-93. PubMed ID: 8898175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
    González-Martín A; Pautier P; Mahner S; Rau J; Colombo N; Ottevanger P; Del Campo JM; Selle F; du Bois A; Gadducci A; García Y; Berton-Rigaud D; Marmé F; Ortega E; Martin N; Bastiere-Truchot L; Kiermaier A; Kurzeder C
    Int J Gynecol Cancer; 2016 Jun; 26(5):898-905. PubMed ID: 27206218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
    Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
    Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
    Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
    Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
    Lund B; Hansen OP; Neijt JP; Theilade K; Hansen M
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():61-2. PubMed ID: 8718427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.
    Garcia AA; O'Meara A; Bahador A; Facio G; Jeffers S; Kim DY; Roman L
    Gynecol Oncol; 2004 May; 93(2):493-8. PubMed ID: 15099968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
    Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
    Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
    Friedlander M; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Varette C; Ripoche V; Kayitalire L
    Ann Oncol; 1998 Dec; 9(12):1343-5. PubMed ID: 9932166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
    Pisano C; Morabito A; Sorio R; Breda E; Lauria R; Gebbia V; Scaltriti L; Scalone S; Zagonel V; Greggi S; Beneduce G; Losito S; Gallo C; Di Maio M; Forestieri V; Pignata S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1021-7. PubMed ID: 19266200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of gemcitabine in ovarian cancer.
    von Minckwitz G; Bauknecht T; Visseren-Grul CM; Neijt JP
    Ann Oncol; 1999 Jul; 10(7):853-5. PubMed ID: 10470434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.
    Markman M; Hall J; Spitz D; Weiner S; Carson L; Van Le L; Baker M
    J Clin Oncol; 2002 May; 20(9):2365-9. PubMed ID: 11981009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
    Ray-Coquard I; Weber B; Cretin J; Haddad-Guichard Z; Lévy E; Hardy-Bessard AC; Gouttebel MC; Geay JF; Aleba A; Orfeuvre H; Agostini C; Provencal J; Ferrero JM; Fric D; Dohollou N; Paraiso D; Salvat J; Pujade-Lauraine E;
    Br J Cancer; 2009 Feb; 100(4):601-7. PubMed ID: 19190632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.